Clinical Trials on Prostate Adenocarcinoma in Poland

Total 1130 results

OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
Pfizer

Terminated

Pre-Prostatectomy Celecoxib or Placebo

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Brown University
AstraZeneca; The Miriam Hospital; Rhode Island Hospital

Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (337)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Eli Lilly and Company

Completed

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Puerto Rico
OHSU Knight Cancer Institute
Astellas Pharma US, Inc.; Oregon Health and Science University

Active, not recruiting

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
OHSU Knight Cancer Institute
The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Progenics Pharmaceuticals, Inc.

Not yet recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Prostate Adenocarcinoma | Castration Resistant Prostate Cancer | Castration Sensitive Prostate Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Switzerland
Jagiellonian University
University Hospital in Krakow

Recruiting

Clinical Application of the J-PET Scanner Prototype (JPET2Clinic)

Prostatic Neoplasms | Prostatic Hyperplasia | Prostate Cancer | Neuroendocrine Tumors | Neuroendocrine Carcinoma | Prostate Cancer Metastatic

Poland
OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER (BALANCE)

PSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer (PCW)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer

United States, Guam
Maria Sklodowska-Curie National Research Institute...

Unknown

Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer

Prostate Cancer

Poland
BioProtect

Completed

Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients (CLP-10095)

Prostate Cancer

Poland, Portugal
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
Jeanne Link
Oregon Health and Science University; OHSU Knight Cancer Institute; OHSU Center...

Approved for marketing

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Prostatic Neoplasms | Prostatic Diseases | Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic

United States
Maria Sklodowska-Curie National Research Institute...

Recruiting

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy (PROSTARE)

Radiotherapy | Local Recurrence of Malignant Tumor of Prostate

Poland
The Greater Poland Cancer Centre

Recruiting

Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer (CYBERPROST)

Prostate Cancer

Poland
The Greater Poland Cancer Centre

Recruiting

Focal Salvage Brachytherapy Study (FocaSaBra) (FocaSaBra)

Prostate Cancer

Poland
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States, Canada
Portland VA Medical Center
National Cancer Institute (NCI); OHSU Knight Cancer Institute; Oregon State University

Completed

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation (PBroC)

Prostate Cancer Prevention

United States
University of Erlangen-Nürnberg Medical School

Unknown

Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy (Prostata-BT-HT)

Prostate Cancer

Germany, Poland
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics...

Active, not recruiting

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States, Canada, Puerto Rico
Genzyme, a Sanofi Company

Completed

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Hormone-refractory Prostate Cancer

United States
UbiVac
Providence Health & Services; Providence Cancer Center, Earle A. Chiles Research... and other collaborators

Completed

Pilot Study of DRibble Vaccine for Prostate Cancer Patients (DRibble)

Adenocarcinoma of the Prostate

United States
Radboud University Medical Center

Not yet recruiting

Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy (AFFIRM)

Prostate Cancer | Prostate Neoplasm

Netherlands
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostatic Adenocarcinoma | Castration Levels of Testosterone

United States, Switzerland, Mexico, Chile, Colombia
Modra Pharmaceuticals

Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States, Germany, Hungary, Poland, Russian Federation, Czechia
Julie Graff, MD
Johns Hopkins University; Merck Sharp & Dohme LLC; Oregon Health and Science... and other collaborators

Recruiting

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Prostate Cancer | Prostate Cancer Metastatic

United States
The Greater Poland Cancer Centre

Completed

Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated (HYPOPROST)

Prostate Cancer

Poland
Terence Friedlander, MD
Janssen Biotech, Inc.

Completed

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Oregon Health and Science University

Completed

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Prostate Cancer | Metastatic, Androgen Independent Prostate Cancer

United States
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Portland VA Medical Center

Completed

Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer

Prostate Cancer | Hereditary Prostate Cancer

United States
Medical University of Bialystok
Medical Research Agency, Poland

Recruiting

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer (PROSPETMR2021)

Prostate Cancer

Poland
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Suspended

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

Canada, United States
BioProtect

Recruiting

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System (CLP-10441)

Prostate Cancer

Ireland, Israel, Netherlands, Poland, Portugal
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Prostate Cancer | Hormone Refractory Prostate Cancer

United States

Clinical Trials on Prostate Adenocarcinoma in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations